Post-market

View Life Sciences by content type:

Latest Life Sciences News

Featured Life Sciences content

Practice notes
As of exit day (31 January 2020) the UK is no longer an EU Member State. However, in accordance with the Withdrawal Agreement, the UK has entered an...
Read More >
9th Nov
Practice notes
Introduction to infringementA patent owner has to prove two elements before it can secure an infringement finding (and then an injunction, damages,...
Read More >
9th Nov
Practice notes
Brexit: The UK's departure from the EU on exit day ie Friday 31 January 2020 has implications for practitioners considering the use of ADR as it may...
Read More >
9th Nov
Practice notes
As of exit day (31 January 2020) the UK is no longer an EU Member State. However, in accordance with the Withdrawal Agreement, the UK has entered an...
Read More >
9th Nov
Practice notes
This Practice Note provides an introduction to retained EU law, which is an entirely new legal concept introduced to UK domestic law in preparation...
Read More >
9th Nov
Practice notes
An intellectual property (IP) owner may choose to license its IP to a third party. This can be an effective route to generating revenue while...
Read More >
Produced in partnership with Jessica Stretch 12th Jan
Practice notes
Brexit: The UK's departure from the EU on exit day, ie Friday 31 January 2020, has implications for practitioners considering applicable law. For...
Read More >
9th Nov
Practice notes
This Practice Note provides an introduction to arbitration and its key features, with a particular focus on arbitration under the law of England and...
Read More >
Produced in partnership with Simmons & Simmons LLP 12th Jan
Practice notes
In order to establish that an unauthorised use or dealing in a product or process amounts to infringement of a patent it is necessary to prove that:•a...
Read More >
9th Nov
Practice notes
A director who is in any way, directly or indirectly, interested in:•a proposed transaction or arrangement with the company of which they are a...
Read More >
9th Nov
Practice notes
What is a company's constitution?A company’s 'constitution' is defined under the Companies Act 2006 (CA 2006) as including:•the company’s articles of...
Read More >
9th Nov
Practice notes
This Practice Note considers the meaning and use of conditions precedent in commercial arrangements. It also considers typical conditions precedent...
Read More >
9th Nov
Practice notes
Unlike many other countries, the UK has no unfair competition law. Brand owners seeking to prevent competitors from marketing ‘copycat’ products or...
Read More >
9th Nov
Practice notes
ContractWhere a contract is made by two or more parties it may contain a promise or obligation made by two or more of those parties. Any such promise...
Read More >
9th Nov

Most recent Post-market content

Practice notes
What does IP completion day mean for medicinal products?11 pm (GMT) on 31 December 2020 marked the end of the implementation period put in place to...
Read More >
11th May
Practice notes
IP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s...
Read More >
6th May
Practice notes
At 11 pm on 31 December 2020 (IP completion day), the UK ceased to be subject to EU law. The UK’s relationship with the EU is now governed by the...
Read More >
Produced in partnership with Oscar Benito of Gavi, the Vaccines Alliance 6th May
Practice notes
ScopeThis Practice Note explains trade mark law on parallel trade. Parallel imports, or ‘grey market’ goods, are genuine goods that are placed on the...
Read More >
Produced in partnership with Taylor Wessing LLP 6th May
Practice notes
The UK regulatory framework for product liability has mainly originated from EU law. Many principles and requirements derived from EU law have been...
Read More >
6th May
Practice notes
Pharmacovigilance is the process of collecting and understanding information relating to the adverse effects of medicinal product throughout their use...
Read More >
Produced in partnership with Eveline Van Keymeulen of Allen & Overy LLP and Jeanne Fabre of Allen & Overy LLP 6th May
Practice notes
This Practice Note summarises the main types of legal action that can be taken against the UK trade in counterfeit goods, the pros and cons of each...
Read More >
Produced in partnership with Taylor Wessing LLP 15th Apr
Practice notes
This Practice Note considers the relevance of the Withdrawal Agreement to the life sciences sector and the respective roles of the EU and UK...
Read More >
12th Apr
Practice notes
IP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s...
Read More >
Produced in partnership with Elisabethann Wright, Marta Miglietti, Fabien Roy, Jane Summerfield, Julia Fraser and Richard Welfare of Hogan Lovells 9th Apr
Practice notes
This Practice Note summarises the law on defective products under the Consumer Protection Act 1987 (CPA 1987) and Council Directive 85/374/EEC (the EU...
Read More >
Produced in partnership with Alison Newstead, Simon Castley and Marisa Pearce of Shook, Hardy & Bacon International LLP 18th Mar
Precedents
1Product recall clause—pro-supplier1.1The Customer shall immediately notify the Supplier if it becomes aware of any complaint or claim which indicates...
Read More >
Produced in partnership with Emma Spence of DWF LLP and David Kidman of DWF LLP 22nd Feb
Q&As
Pharmacovigilance (PV) is the practice of monitoring the effects of medicinal drugs after they have been licensed for use to identify and evaluate...
Read More >
Produced in partnership with Rishi Wadwha of International Association of Privacy Professionals 19th Feb
Q&As
All medicinal products in the EU are subject to a strict testing and assessment of their quality, efficacy and safety before being authorised. Once...
Read More >
13th Feb
Q&As
Article 104(3) of Directive 2001/83/EC (consolidated version 26.07.2019), the Pharmaceutical Code establishes the requirement for the marketing...
Read More >
13th Feb
Q&As
The following Practice Notes are useful when considering the current position regarding product liability in the life sciences sector (although the...
Read More >
13th Feb
Q&As
Article 23(2) of Directive 2001/83/EC (consolidated version 26.07.2019), the Pharmaceutical Code requires the marketing authorisation holder (MAH) to...
Read More >
22nd Dec
Q&As
The Guideline on good pharmacovigilance practices (GVP) (PV Guidance) provides that a marketing authorization holder (MAH) may subcontract certain...
Read More >
29th Nov

Popular documents